Literature DB >> 19396153

TRPM1 (Melastatin-1/MLSN1) mRNA expression in Spitz nevi and nodular melanomas.

Lori A Erickson1, Gary A Letts, Sonali M Shah, Jeffrey B Shackelton, Lyn M Duncan.   

Abstract

The transient receptor potential cation channel, subfamily M, member 1 (TRPM1/Melastatin-1/MLSN-1) expression has been shown to have prognostic utility in the evaluation of primary cutaneous melanoma. We analyzed a series of spindled and epithelioid cell nevi (Spitz) and primary cutaneous nodular melanomas to determine whether the expression of TRPM1 mRNA may be useful in distinguishing between Spitz nevi and nodular melanomas and to further examine the patterns of TRPM1 mRNA expression in cutaneous melanocytic proliferations. Formalin-fixed, paraffin-embedded tissues from 95 Spitz nevi and 33 nodular melanomas were analyzed for the expression of TRPM1 mRNA by in situ hybridization using (35)S-labeled riboprobes. Ubiquitous melanocytic expression of TRPM1 mRNA was observed in 56 of 95 (59%) Spitz nevi and 4 of 33 (12%) nodular melanomas. Diffusely scattered loss of TRPM1 mRNA was identified in 38 of 95 (40%) Spitz nevi and 2 of 33 (6%) nodular melanomas. Regional loss of the TRPM1 mRNA expression by a significant subset of dermal tumor cells or a complete absence of TRPM1 expression by the dermal tumor was identified in 27 of 33 (82%) nodular melanomas, but only 1 of 95 (1%) Spitz nevi. These findings suggest that the pattern of TRPM1 mRNA expression may be helpful in the differentiation of Spitz nevi and nodular melanomas. Of the 16 patients who experienced metastasis, 15 (94%) had primary tumors that displayed reduced MLSN mRNA expression by all or a part of the dermal tumor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396153     DOI: 10.1038/modpathol.2009.56

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

1.  Transient receptor potential melastatin 1 (TRPM1) is an ion-conducting plasma membrane channel inhibited by zinc ions.

Authors:  Sachar Lambert; Anna Drews; Oleksandr Rizun; Thomas F J Wagner; Annette Lis; Stefanie Mannebach; Sandra Plant; Melanie Portz; Marcel Meissner; Stephan E Philipp; Johannes Oberwinkler
Journal:  J Biol Chem       Date:  2011-01-28       Impact factor: 5.157

Review 2.  Role of TRP ion channels in cancer and tumorigenesis.

Authors:  George Shapovalov; Abigael Ritaine; Roman Skryma; Natalia Prevarskaya
Journal:  Semin Immunopathol       Date:  2016-02-03       Impact factor: 9.623

Review 3.  The role of Orai-STIM calcium channels in melanocytes and melanoma.

Authors:  Hedwig Stanisz; Adina Vultur; Meenhard Herlyn; Alexander Roesch; Ivan Bogeski
Journal:  J Physiol       Date:  2016-04-06       Impact factor: 5.182

4.  Role of TRPM in melanocytes and melanoma.

Authors:  Huazhang Guo; John Andrew Carlson; Andrzej Slominski
Journal:  Exp Dermatol       Date:  2012-09       Impact factor: 3.960

5.  TRPA1 is functionally expressed in melanoma cells but is not critical for impaired proliferation caused by allyl isothiocyanate or cinnamaldehyde.

Authors:  Beatrice Oehler; Anja Scholze; Michael Schaefer; Kerstin Hill
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-03-18       Impact factor: 3.000

6.  Paraganglioma-like dermal melanocytic tumor: a case report with particular features.

Authors:  Anca Maria Cimpean; Raluca Ceauşu; Marius Raica
Journal:  Int J Clin Exp Pathol       Date:  2009-11-20

7.  Autoantibody against transient receptor potential M1 cation channels of retinal ON bipolar cells in paraneoplastic vitelliform retinopathy.

Authors:  Yujuan Wang; Mones S Abu-Asab; Wei Li; Mary E Aronow; Arun D Singh; Chi-Chao Chan
Journal:  BMC Ophthalmol       Date:  2012-11-13       Impact factor: 2.209

8.  Autoantibodies in Melanoma-Associated Retinopathy Recognize an Epitope Conserved Between TRPM1 and TRPM3.

Authors:  Robert M Duvoisin; Tammie L Haley; Gaoying Ren; Iwona Strycharska-Orczyk; James P Bonaparte; Catherine W Morgans
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-05-01       Impact factor: 4.799

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.